Latest news

• Roche gets first approval for haemophilia A therapy

  The market for haemophilia A with inhibitors is currently dominated by Shire and Novo Nordisk with their Feiba and NovoSeven bypassing agents (PBAs).

• Shire wins block of Roche' 'misinformation' over emicizumab

  The market for haemophilia A with inhibitors is currently dominated by Shire and Novo Nordisk with their Feiba and NovoSeven bypassing agents (PBAs).

• Patient death mars Roche haemophilia drug trial

  for breakthrough bleeds which includes Shire's Feiba and Novo Nordisk's NovoSeven. ... Analysts have previously suggested that emicizumab could attack around half the revenues of NovoSeven, which made sales of almost $1.4bn in 2016, and eat into the

• Novo Nordisk wins US approval for haemophilia treatment

  The drug will be used in conjunction with Novo's MixPro, the pre-filled device that was launched earlier this year and is already in use with the company's NovoSeven ... Novo's existing haemophilia A and B treatment for patients with inhibitors, NovoSeven

• EMA backs drugs from Novo, Otsuka, AZ, Janssen, GSK

  Normally associated with diabetes medicines, Novo has built a burgeoning business in the area of bleeding disorders, led by NovoSeven, which made $1.4bn in revenues in 2012.